SG Americas Securities’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-15,235
Closed -$672K 3566
2025
Q1
$672K Buy
15,235
+9,409
+162% +$433K ﹤0.01% 1532
2024
Q4
$210K Buy
+5,826
New +$204K ﹤0.01% 2112
2024
Q2
Sell
-4,673
Closed -$230K 3293
2024
Q1
$230K Buy
4,673
+358
+8% +$16.6K ﹤0.01% 1876
2023
Q4
$157K Buy
+4,315
New +$113K ﹤0.01% 2383
2023
Q1
Sell
-5,403
Closed -$141K 3548
2022
Q4
$141K Buy
+5,403
New +$133K ﹤0.01% 2483
2022
Q3
Sell
-7,335
Closed -$181K 3547
2022
Q2
$181K Sell
7,335
-15,475
-68% -$566K ﹤0.01% 2738
2022
Q1
$1.29M Sell
22,810
-10,477
-31% -$600K 0.01% 1237
2021
Q4
$2.06M Buy
33,287
+12,179
+58% +$806K 0.01% 1054
2021
Q3
$1.34M Buy
21,108
+1,782
+9% +$137K 0.01% 1654
2021
Q2
$1.59M Buy
19,326
+2,451
+15% +$186K 0.01% 1260
2021
Q1
$1.24M Sell
16,875
-6,198
-27% -$485K 0.01% 1377
2020
Q4
$1.67M Sell
23,073
-18,231
-44% -$1.17M 0.01% 1196
2020
Q3
$1.97M Buy
41,304
+29,693
+256% +$1.26M 0.01% 748
2020
Q2
$488K Buy
11,611
+6,733
+138% +$240K ﹤0.01% 2117
2020
Q1
$132K Buy
+4,878
New +$159K ﹤0.01% 2793

Other funds holding SWTX

SG Americas Securities's SWTX Position: Q2 2025 in Review

SG Americas Securities sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 15,235 shares — an estimated $672K sold.

SG Americas Securities first reported a position in SWTX in Q1 2020 and held it in 15 quarters. The position peaked at $2.06M in Q4 2021. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • SG Americas Securities reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 15,235 SpringWorks Therapeutics shares in Q2 2025, an estimated $672K.
  • SG Americas Securities first reported a position in SpringWorks Therapeutics in Q1 2020 and held it in 15 quarters.
  • SG Americas Securities's SpringWorks Therapeutics position peaked at $2.06M in Q4 2021.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.